Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Tislelizumab-related enteritis successfully treated with adalimumab: A case report
Na Chen, Min-Jia Qian, Ru-Hui Zhang, Qi-Qi Gao, Chao-Chao He, Ya-Ke Yao, Jian-Ying Zhou, Hua Zhou
Na Chen, Chao-Chao He, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Min-Jia Qian, Ru-Hui Zhang, Ya-Ke Yao, Jian-Ying Zhou, Hua Zhou, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Min-Jia Qian, Department of Critical Care Medicine, Zhuji People’s Hospital, Shaoxing 311800, Zhejiang Province, China
Qi-Qi Gao, Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Chao-Chao He, Department of Pharmacy, Yiwu Central Hospital, Jinhua 322000, Zhejiang Province, China
Author contributions: All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Hua Zhou, MD, Associate Chief Physician, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. zhouhua1@zju.edu.cn
Received: April 22, 2022
Peer-review started: April 22, 2022
First decision: June 8, 2022
Revised: June 17, 2022
Accepted: August 25, 2022
Article in press: August 25, 2022
Published online: October 6, 2022
Processing time: 155 Days and 21.4 Hours
